The Bruton tyrosine kinase inhibitor zanubrutinib (BGB-3111) demonstrated synergies with other anti-lymphoma targeted agents

Tarantelli, C; Zhang, L; Curti, E; Gaudio, E; Spriano, F; Priebe, V; Cascione, L; Arribas, AJ; Zucca, E; Rossi, D; Stathis, A; Bertoni, F

Bertoni, F (reprint author), Univ Svizzera Italiana, Inst Oncol Res, Bellinzona, Switzerland.

HAEMATOLOGICA, 2019; 104 (7):